SynAb™ Technology

Biosion's Synergistic Antibody Technology is derived from the principles of natural synergistic activities of polyclonal antibodies developed using immunogens. Our proprietary H³ screening platform is able to identify synergistic activities between monoclonal antibodies.

The advantage of Synergistic Antibodies lies not only in their ability to provide the distinct merits of polyclonal (affinity, neutralizing activity) and monoclonal (specificity) antibodies, but also in their ability to diminish their individual weaknesses. The synergistic combination of specific antibodies creates a biological product that is greater than the sum of the individual monoclonal antibody components.